Liposarcoma - Revision history

Michael at 14:12, 11 April 2022

2022-04-11T14:12:57Z

← Older revision		Revision as of 14:12, 11 April 2022
Line 39:		Line 39:
	**Extremity: good - disease specific 5-year survival ~ 92%.<ref>{{Cite journal \| last1 = Lietman \| first1 = SA. \| last2 = Barsoum \| first2 = WK. \| last3 = Goldblum \| first3 = JR. \| last4 = Marks \| first4 = KE. \| last5 = Mascha \| first5 = E. \| last6 = Sundaram \| first6 = M. \| last7 = Muschler \| first7 = G. \| title = A 20-year retrospective review of surgically treated liposarcoma at the Cleveland Clinic. \| journal = Orthopedics \| volume = 30 \| issue = 3 \| pages = 227-34 \| month = Mar \| year = 2007 \| doi = \| PMID = 17375550 }}</ref>		**Extremity: good - disease specific 5-year survival ~ 92%.<ref>{{Cite journal \| last1 = Lietman \| first1 = SA. \| last2 = Barsoum \| first2 = WK. \| last3 = Goldblum \| first3 = JR. \| last4 = Marks \| first4 = KE. \| last5 = Mascha \| first5 = E. \| last6 = Sundaram \| first6 = M. \| last7 = Muschler \| first7 = G. \| title = A 20-year retrospective review of surgically treated liposarcoma at the Cleveland Clinic. \| journal = Orthopedics \| volume = 30 \| issue = 3 \| pages = 227-34 \| month = Mar \| year = 2007 \| doi = \| PMID = 17375550 }}</ref>
	**D-dimer (serum) useful; elevated levels in keeping with liposarcoma.		**D-dimer (serum) useful; elevated levels in keeping with liposarcoma.
	***Cut ~~point~~ 0.41 μg/ml for metastasis: sensitivity 0.83 and specificity 0.57.<ref name=pmid22044610>{{cite journal \|authors=Morii T, Mochizuki K, Tajima T, Ichimura S, Satomi K \|title=D-dimer levels as a prognostic factor for determining oncological outcomes in musculoskeletal sarcoma \|journal=BMC Musculoskelet Disord \|volume=12 \|issue= \|pages=250 \|date=November 2011 \|pmid=22044610 \|pmc=3226444 \|doi=10.1186/1471-2474-12-250 \|url=}}</ref>		***Cut-off value 0.41 μg/ml for metastasis: sensitivity 0.83 and specificity 0.57.<ref name=pmid22044610>{{cite journal \|authors=Morii T, Mochizuki K, Tajima T, Ichimura S, Satomi K \|title=D-dimer levels as a prognostic factor for determining oncological outcomes in musculoskeletal sarcoma \|journal=BMC Musculoskelet Disord \|volume=12 \|issue= \|pages=250 \|date=November 2011 \|pmid=22044610 \|pmc=3226444 \|doi=10.1186/1471-2474-12-250 \|url=}}</ref>
	***Cut ~~point~~ 0.80 μg/ml for total survival: sensitivity 0.80 and specificity 0.75.<ref name=pmid22044610/>		***Cut-off value 0.80 μg/ml for total survival: sensitivity 0.80 and specificity 0.75.<ref name=pmid22044610/>

	Notes:		Notes:
	*Retroperitoneal sarcomas: #1: liposarcoma, #2: [[pleomorphic undifferentiated sarcoma]], #3: [[leiomyosarcoma]], #4: [[MPNST]].		*Retroperitoneal sarcomas: #1: liposarcoma, #2: [[pleomorphic undifferentiated sarcoma]], #3: [[leiomyosarcoma]], #4: [[MPNST]].
	**Extremely rare in retroperitoneum: [[synovial sarcoma]].		**Extremely rare in retroperitoneum: [[synovial sarcoma]].


	==Gross==		==Gross==

Michael: D-dimer

2022-04-11T14:11:12Z

D-dimer

← Older revision		Revision as of 14:11, 11 April 2022
Line 22:		Line 22:
	\| Symptoms =		\| Symptoms =
	\| Prevalence = most common retroperitoneal sarcoma, uncommon overall		\| Prevalence = most common retroperitoneal sarcoma, uncommon overall
	\| Bloodwork =		\| Bloodwork = D-dimer elevated
	\| Rads = thick septae or nodules in a fatty appearing lesion		\| Rads = thick septae or nodules in a fatty appearing lesion
	\| Endoscopy =		\| Endoscopy =
Line 38:		Line 38:
	**Retroperitoneal: poor.		**Retroperitoneal: poor.
	**Extremity: good - disease specific 5-year survival ~ 92%.<ref>{{Cite journal \| last1 = Lietman \| first1 = SA. \| last2 = Barsoum \| first2 = WK. \| last3 = Goldblum \| first3 = JR. \| last4 = Marks \| first4 = KE. \| last5 = Mascha \| first5 = E. \| last6 = Sundaram \| first6 = M. \| last7 = Muschler \| first7 = G. \| title = A 20-year retrospective review of surgically treated liposarcoma at the Cleveland Clinic. \| journal = Orthopedics \| volume = 30 \| issue = 3 \| pages = 227-34 \| month = Mar \| year = 2007 \| doi = \| PMID = 17375550 }}</ref>		**Extremity: good - disease specific 5-year survival ~ 92%.<ref>{{Cite journal \| last1 = Lietman \| first1 = SA. \| last2 = Barsoum \| first2 = WK. \| last3 = Goldblum \| first3 = JR. \| last4 = Marks \| first4 = KE. \| last5 = Mascha \| first5 = E. \| last6 = Sundaram \| first6 = M. \| last7 = Muschler \| first7 = G. \| title = A 20-year retrospective review of surgically treated liposarcoma at the Cleveland Clinic. \| journal = Orthopedics \| volume = 30 \| issue = 3 \| pages = 227-34 \| month = Mar \| year = 2007 \| doi = \| PMID = 17375550 }}</ref>
			**D-dimer (serum) useful; elevated levels in keeping with liposarcoma.
			***Cut point 0.41 μg/ml for metastasis: sensitivity 0.83 and specificity 0.57.<ref name=pmid22044610>{{cite journal \|authors=Morii T, Mochizuki K, Tajima T, Ichimura S, Satomi K \|title=D-dimer levels as a prognostic factor for determining oncological outcomes in musculoskeletal sarcoma \|journal=BMC Musculoskelet Disord \|volume=12 \|issue= \|pages=250 \|date=November 2011 \|pmid=22044610 \|pmc=3226444 \|doi=10.1186/1471-2474-12-250 \|url=}}</ref>
			***Cut point 0.80 μg/ml for total survival: sensitivity 0.80 and specificity 0.75.<ref name=pmid22044610/>

	Notes:		Notes:
	*Retroperitoneal sarcomas: #1: liposarcoma, #2: [[pleomorphic undifferentiated sarcoma]], #3: [[leiomyosarcoma]], #4: [[MPNST]].		*Retroperitoneal sarcomas: #1: liposarcoma, #2: [[pleomorphic undifferentiated sarcoma]], #3: [[leiomyosarcoma]], #4: [[MPNST]].
	**Extremely rare in retroperitoneum: [[synovial sarcoma]].		**Extremely rare in retroperitoneum: [[synovial sarcoma]].


	==Gross==		==Gross==

Michael: /* General */

2014-09-19T03:15:56Z

General

← Older revision		Revision as of 03:15, 19 September 2014
Line 35:		Line 35:
	*Most common malignant sarcoma in the retroperitoneum.		*Most common malignant sarcoma in the retroperitoneum.
	*Not all (large) retroperitoneal adipocytic tumours are liposarcomas.		*Not all (large) retroperitoneal adipocytic tumours are liposarcomas.
	*Prognosis - good-to-~~moderate dependent on stage~~.		*Prognosis - dependent on the location.
			**Retroperitoneal: poor.
			**Extremity: good - disease specific 5-year survival ~ 92%.<ref>{{Cite journal \| last1 = Lietman \| first1 = SA. \| last2 = Barsoum \| first2 = WK. \| last3 = Goldblum \| first3 = JR. \| last4 = Marks \| first4 = KE. \| last5 = Mascha \| first5 = E. \| last6 = Sundaram \| first6 = M. \| last7 = Muschler \| first7 = G. \| title = A 20-year retrospective review of surgically treated liposarcoma at the Cleveland Clinic. \| journal = Orthopedics \| volume = 30 \| issue = 3 \| pages = 227-34 \| month = Mar \| year = 2007 \| doi = \| PMID = 17375550 }}</ref>

	Notes:		Notes:

Michael: /* General */

2014-09-19T03:11:48Z

General

← Older revision		Revision as of 03:11, 19 September 2014
Line 36:		Line 36:
	*Not all (large) retroperitoneal adipocytic tumours are liposarcomas.		*Not all (large) retroperitoneal adipocytic tumours are liposarcomas.
	*Prognosis - good-to-moderate dependent on stage.		*Prognosis - good-to-moderate dependent on stage.
	**Five year survival for retroperitoneal liposarcoma in one series (per AJCC 6th edition): stage I = 96%, stage II = 58% stage III = 42%.<ref name=pmid19101765>{{Cite journal \| last1 = Anaya \| first1 = DA. \| last2 = Lahat \| first2 = G. \| last3 = Wang \| first3 = X. \| last4 = Xiao \| first4 = L. \| last5 = Tuvin \| first5 = D. \| last6 = Pisters \| first6 = PW. \| last7 = Lev \| first7 = DC. \| last8 = Pollock \| first8 = RE. \| title = Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. \| journal = Ann Surg Oncol \| volume = 16 \| issue = 3 \| pages = 667-75 \| month = Mar \| year = 2009 \| doi = 10.1245/s10434-008-0250-2 \| PMID = 19101765 }}</ref>

	Notes:		Notes:

Michael at 03:10, 19 September 2014

2014-09-19T03:10:21Z

← Older revision		Revision as of 03:10, 19 September 2014
Line 36:		Line 36:
	*Not all (large) retroperitoneal adipocytic tumours are liposarcomas.		*Not all (large) retroperitoneal adipocytic tumours are liposarcomas.
	*Prognosis - good-to-moderate dependent on stage.		*Prognosis - good-to-moderate dependent on stage.
	**Five year survival in one series (per AJCC 6th edition): stage I = 96%, stage II = 58% stage III = 42%.<ref name=pmid19101765>{{Cite journal \| last1 = Anaya \| first1 = DA. \| last2 = Lahat \| first2 = G. \| last3 = Wang \| first3 = X. \| last4 = Xiao \| first4 = L. \| last5 = Tuvin \| first5 = D. \| last6 = Pisters \| first6 = PW. \| last7 = Lev \| first7 = DC. \| last8 = Pollock \| first8 = RE. \| title = Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. \| journal = Ann Surg Oncol \| volume = 16 \| issue = 3 \| pages = 667-75 \| month = Mar \| year = 2009 \| doi = 10.1245/s10434-008-0250-2 \| PMID = 19101765 }}</ref>		**Five year survival for retroperitoneal liposarcoma in one series (per AJCC 6th edition): stage I = 96%, stage II = 58% stage III = 42%.<ref name=pmid19101765>{{Cite journal \| last1 = Anaya \| first1 = DA. \| last2 = Lahat \| first2 = G. \| last3 = Wang \| first3 = X. \| last4 = Xiao \| first4 = L. \| last5 = Tuvin \| first5 = D. \| last6 = Pisters \| first6 = PW. \| last7 = Lev \| first7 = DC. \| last8 = Pollock \| first8 = RE. \| title = Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. \| journal = Ann Surg Oncol \| volume = 16 \| issue = 3 \| pages = 667-75 \| month = Mar \| year = 2009 \| doi = 10.1245/s10434-008-0250-2 \| PMID = 19101765 }}</ref>

	Notes:		Notes:
	*Retroperitoneal sarcomas: #1: liposarcoma, #2: [[pleomorphic undifferentiated sarcoma]], #3: leiomyosarcoma, #4: [[MPNST]].		*Retroperitoneal sarcomas: #1: liposarcoma, #2: [[pleomorphic undifferentiated sarcoma]], #3: [[leiomyosarcoma]], #4: [[MPNST]].
	**Extremely rare in retroperitoneum: [[synovial sarcoma]].		**Extremely rare in retroperitoneum: [[synovial sarcoma]].

Michael: /* General */

2014-09-19T03:09:06Z

General

← Older revision		Revision as of 03:09, 19 September 2014
Line 36:		Line 36:
	*Not all (large) retroperitoneal adipocytic tumours are liposarcomas.		*Not all (large) retroperitoneal adipocytic tumours are liposarcomas.
	*Prognosis - good-to-moderate dependent on stage.		*Prognosis - good-to-moderate dependent on stage.
	**Five year survival in one series: stage I = 96%, stage II = 58% stage III = 42%.<ref name=pmid19101765>{{Cite journal \| last1 = Anaya \| first1 = DA. \| last2 = Lahat \| first2 = G. \| last3 = Wang \| first3 = X. \| last4 = Xiao \| first4 = L. \| last5 = Tuvin \| first5 = D. \| last6 = Pisters \| first6 = PW. \| last7 = Lev \| first7 = DC. \| last8 = Pollock \| first8 = RE. \| title = Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. \| journal = Ann Surg Oncol \| volume = 16 \| issue = 3 \| pages = 667-75 \| month = Mar \| year = 2009 \| doi = 10.1245/s10434-008-0250-2 \| PMID = 19101765 }}</ref>		**Five year survival in one series (per AJCC 6th edition): stage I = 96%, stage II = 58% stage III = 42%.<ref name=pmid19101765>{{Cite journal \| last1 = Anaya \| first1 = DA. \| last2 = Lahat \| first2 = G. \| last3 = Wang \| first3 = X. \| last4 = Xiao \| first4 = L. \| last5 = Tuvin \| first5 = D. \| last6 = Pisters \| first6 = PW. \| last7 = Lev \| first7 = DC. \| last8 = Pollock \| first8 = RE. \| title = Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. \| journal = Ann Surg Oncol \| volume = 16 \| issue = 3 \| pages = 667-75 \| month = Mar \| year = 2009 \| doi = 10.1245/s10434-008-0250-2 \| PMID = 19101765 }}</ref>

	Notes:		Notes:

Michael: /* General */

2014-09-19T03:08:37Z

General

← Older revision		Revision as of 03:08, 19 September 2014
Line 35:		Line 35:
	*Most common malignant sarcoma in the retroperitoneum.		*Most common malignant sarcoma in the retroperitoneum.
	*Not all (large) retroperitoneal adipocytic tumours are liposarcomas.		*Not all (large) retroperitoneal adipocytic tumours are liposarcomas.
	*Prognosis - good-to-~~poor~~ dependent on stage.		*Prognosis - good-to-moderate dependent on stage.
	**~~AJCC 6th staging~~: stage I = 96%, stage II = 58% stage III = 42%.<ref name=pmid19101765>{{Cite journal \| last1 = Anaya \| first1 = DA. \| last2 = Lahat \| first2 = G. \| last3 = Wang \| first3 = X. \| last4 = Xiao \| first4 = L. \| last5 = Tuvin \| first5 = D. \| last6 = Pisters \| first6 = PW. \| last7 = Lev \| first7 = DC. \| last8 = Pollock \| first8 = RE. \| title = Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. \| journal = Ann Surg Oncol \| volume = 16 \| issue = 3 \| pages = 667-75 \| month = Mar \| year = 2009 \| doi = 10.1245/s10434-008-0250-2 \| PMID = 19101765 }}</ref>		**Five year survival in one series: stage I = 96%, stage II = 58% stage III = 42%.<ref name=pmid19101765>{{Cite journal \| last1 = Anaya \| first1 = DA. \| last2 = Lahat \| first2 = G. \| last3 = Wang \| first3 = X. \| last4 = Xiao \| first4 = L. \| last5 = Tuvin \| first5 = D. \| last6 = Pisters \| first6 = PW. \| last7 = Lev \| first7 = DC. \| last8 = Pollock \| first8 = RE. \| title = Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. \| journal = Ann Surg Oncol \| volume = 16 \| issue = 3 \| pages = 667-75 \| month = Mar \| year = 2009 \| doi = 10.1245/s10434-008-0250-2 \| PMID = 19101765 }}</ref>

	Notes:		Notes:

Michael: /* General */

2014-09-19T03:07:57Z

General

← Older revision		Revision as of 03:07, 19 September 2014
Line 35:		Line 35:
	*Most common malignant sarcoma in the retroperitoneum.		*Most common malignant sarcoma in the retroperitoneum.
	*Not all (large) retroperitoneal adipocytic tumours are liposarcomas.		*Not all (large) retroperitoneal adipocytic tumours are liposarcomas.
			*Prognosis - good-to-poor dependent on stage.
			**AJCC 6th staging: stage I = 96%, stage II = 58% stage III = 42%.<ref name=pmid19101765>{{Cite journal \| last1 = Anaya \| first1 = DA. \| last2 = Lahat \| first2 = G. \| last3 = Wang \| first3 = X. \| last4 = Xiao \| first4 = L. \| last5 = Tuvin \| first5 = D. \| last6 = Pisters \| first6 = PW. \| last7 = Lev \| first7 = DC. \| last8 = Pollock \| first8 = RE. \| title = Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. \| journal = Ann Surg Oncol \| volume = 16 \| issue = 3 \| pages = 667-75 \| month = Mar \| year = 2009 \| doi = 10.1245/s10434-008-0250-2 \| PMID = 19101765 }}</ref>

	Notes:		Notes:

Michael: /* IHC */

2014-09-19T02:56:08Z

IHC

← Older revision		Revision as of 02:56, 19 September 2014
Line 125:		Line 125:
	==IHC==		==IHC==
	*MDM2 +ve.<ref name=pmid24227706>{{Cite journal \| last1 = Mariño-Enríquez \| first1 = A. \| last2 = Hornick \| first2 = JL. \| last3 = Dal Cin \| first3 = P. \| last4 = Cibas \| first4 = ES. \| last5 = Qian \| first5 = X. \| title = Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. \| journal = Cancer Cytopathol \| volume = 122 \| issue = 2 \| pages = 128-37 \| month = Feb \| year = 2014 \| doi = 10.1002/cncy.21362 \| PMID = 24227706 }}</ref>		*MDM2 +ve.<ref name=pmid24227706>{{Cite journal \| last1 = Mariño-Enríquez \| first1 = A. \| last2 = Hornick \| first2 = JL. \| last3 = Dal Cin \| first3 = P. \| last4 = Cibas \| first4 = ES. \| last5 = Qian \| first5 = X. \| title = Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. \| journal = Cancer Cytopathol \| volume = 122 \| issue = 2 \| pages = 128-37 \| month = Feb \| year = 2014 \| doi = 10.1002/cncy.21362 \| PMID = 24227706 }}</ref>
	*CDK4 +ve.		*CDK4 +ve.<ref name=pmid24227706/>
	*S-100 +ve ~1/3 of the time.~~<ref name=pmid24227706/>~~		*S-100 +ve ~1/3 of the time.

	==See also==		==See also==

Michael: /* IHC */

2014-09-19T02:55:56Z

IHC

← Older revision		Revision as of 02:55, 19 September 2014
Line 124:		Line 124:

	==IHC==		==IHC==
	*~~IHC is~~ of ~~limited value~~.		*MDM2 +ve.<ref name=pmid24227706>{{Cite journal \| last1 = Mariño-Enríquez \| first1 = A. \| last2 = Hornick \| first2 = JL. \| last3 = Dal Cin \| first3 = P. \| last4 = Cibas \| first4 = ES. \| last5 = Qian \| first5 = X. \| title = Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. \| journal = Cancer Cytopathol \| volume = 122 \| issue = 2 \| pages = 128-37 \| month = Feb \| year = 2014 \| doi = 10.1002/cncy.21362 \| PMID = 24227706 }}</ref>
			*CDK4 +ve.
	*S-100 +ve ~1/3 of the time.		*S-100 +ve ~1/3 of the time.<ref name=pmid24227706/>
	*Reticulin ???.

	==See also==		==See also==